Mitochondrie jako zásahové místo terapie rakoviny

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F86652036%3A_____%2F09%3A00325040" target="_blank" >RIV/86652036:_____/09:00325040 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Mitochondria as targets for cancer therapy

Popis výsledku v původním jazyce

Mitochondria have recently emerged as intriguing targets for anticancer drugs. A variety of compounds, termed mitocans, have been identified that act via mitochondria. They destabilise mitochondria and cause apoptosis, which is, in some cases, selectivefor cancer cells. Mitochondria are the powerhouse of the cell, as well as the source of mediators of apoptosis. Individual types of cancers are complex and can differ considerably in their array of DNA mutations, harbouring different sets of genetic causes. This indicates that it will be very unlikely to cure cancer by drugs targeting only a few gene products or single pathways that are essential for tumour survival. What is needed then is an invariant target, common to all cells, but which is predominantly only affected by drugs when delivered inside the cancer cells. Such targets appear to be mitochondria, with very rare mutations, and mitocans can be expected to be efficient drugs for different types of the neoplastic disease

Název v anglickém jazyce

Mitochondria as targets for cancer therapy

Popis výsledku anglicky

Mitochondria have recently emerged as intriguing targets for anticancer drugs. A variety of compounds, termed mitocans, have been identified that act via mitochondria. They destabilise mitochondria and cause apoptosis, which is, in some cases, selectivefor cancer cells. Mitochondria are the powerhouse of the cell, as well as the source of mediators of apoptosis. Individual types of cancers are complex and can differ considerably in their array of DNA mutations, harbouring different sets of genetic causes. This indicates that it will be very unlikely to cure cancer by drugs targeting only a few gene products or single pathways that are essential for tumour survival. What is needed then is an invariant target, common to all cells, but which is predominantly only affected by drugs when delivered inside the cancer cells. Such targets appear to be mitochondria, with very rare mutations, and mitocans can be expected to be efficient drugs for different types of the neoplastic disease

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Nutrition & Food Research

ISSN

1613-4125

e-ISSN

—

Svazek periodika

53

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

19

Strana od-do

—

Kód UT WoS článku

000262869400003

EID výsledku v databázi Scopus

—